HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Josef Pichler Selected Research

Glioblastoma (Glioblastoma Multiforme)

3/2022MRI Response Assessment in Glioblastoma Patients Treated with Dendritic-Cell-Based Immunotherapy.
1/2019A Randomized Phase II Trial (TAMIGA) Evaluating the Efficacy and Safety of Continuous Bevacizumab Through Multiple Lines of Treatment for Recurrent Glioblastoma.
10/2018Audencel Immunotherapy Based on Dendritic Cells Has No Effect on Overall and Progression-Free Survival in Newly Diagnosed Glioblastoma: A Phase II Randomized Trial.
9/2015Prognostic quality of activating TERT promoter mutations in glioblastoma: interaction with the rs2853669 polymorphism and patient age at diagnosis.
5/2015MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial.
12/2014A phase II, randomized, study of weekly APG101+reirradiation versus reirradiation in progressive glioblastoma.
5/2014Can bevacizumab prolong survival for glioblastoma patients through multiple lines of therapy?
5/2013MRI assessment of relapsed glioblastoma during treatment with bevacizumab: volumetric measurement of enhanced and FLAIR lesions for evaluation of response and progression--a pilot study.
4/2013Prognostic significance of telomerase-associated parameters in glioblastoma: effect of patient age.
1/2011[Drug therapy of patients with recurrent glioblastoma: is there any evidence?].
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Josef Pichler Research Topics

Disease

11Glioblastoma (Glioblastoma Multiforme)
03/2022 - 01/2010
10Neoplasms (Cancer)
10/2022 - 01/2007
5Glioma (Gliomas)
09/2015 - 05/2006
2Meningioma (Meningiomas)
01/2022 - 11/2018
2Disease Progression
01/2019 - 05/2014
2Colorectal Neoplasms (Colorectal Cancer)
05/2014 - 02/2012
2Neoplasm Metastasis (Metastasis)
04/2013 - 02/2012
1Oligodendroglioma
10/2022
1Fatigue
01/2022
1Brain Neoplasms (Brain Tumor)
01/2022
1Lymphoma (Lymphomas)
07/2019
1Brain Edema (Cerebral Edema)
04/2013
1Thyroid Neoplasms (Thyroid Cancer)
02/2012
1Choriocarcinoma
02/2012
1Melanoma (Melanoma, Malignant)
02/2012
1Lung Neoplasms (Lung Cancer)
02/2012
1Ovarian Neoplasms (Ovarian Cancer)
02/2012
1Sarcoma (Soft Tissue Sarcoma)
06/2007

Drug/Important Bio-Agent (IBA)

4Temozolomide (Temodar)FDA LinkGeneric
01/2019 - 05/2006
4Bevacizumab (Avastin)FDA Link
01/2019 - 06/2011
3Telomerase (Telomerase Reverse Transcriptase)IBA
11/2018 - 04/2013
3Biomarkers (Surrogate Marker)IBA
09/2015 - 12/2014
3Proteins (Proteins, Gene)FDA Link
12/2014 - 01/2010
2Lomustine (CCNU)FDA Link
01/2019 - 05/2014
1Isocitrate Dehydrogenase (Isocitrate Dehydrogenase (NAD+))IBA
10/2022
1TrabectedinIBA
01/2022
1YK 4-279IBA
11/2018
1Proto-Oncogene Proteins c-etsIBA
11/2018
1Cancer VaccinesIBA
10/2018
1hydrogen sulfite (bisulfite)IBA
10/2018
1L 644711 (B-3(+))IBA
05/2015
1APG101IBA
12/2014
1Fas Ligand Protein (Fas Ligand)IBA
12/2014
1Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
05/2014
1Intercellular Signaling Peptides and Proteins (Growth Factors)IBA
01/2014
1Monoclonal AntibodiesIBA
05/2013
1Mutant Proteins (Protein, Mutant)IBA
02/2012
1Alkylating AgentsIBA
01/2010
1O-(6)-methylguanineIBA
01/2010
1DNA (Deoxyribonucleic Acid)IBA
01/2010
1Protein MethyltransferasesIBA
01/2010
1MethyltransferasesIBA
01/2010
1Somatostatin Receptors (Somatostatin Receptor)IBA
06/2007
1pentetreotide (OctreoScan)FDA Link
06/2007
1TrabedersenIBA
01/2007
1Transforming Growth Factor beta2IBA
01/2007

Therapy/Procedure

6Therapeutics
01/2022 - 01/2010
4Radiotherapy
01/2019 - 06/2007
3Immunotherapy
03/2022 - 10/2018
2Chemoradiotherapy
10/2022 - 05/2015
2Drug Therapy (Chemotherapy)
01/2011 - 05/2006
1Re-Irradiation
12/2014
1Aftercare (After-Treatment)
06/2007